Literature DB >> 35755229

Ticagrelor Induced Angioedema Following Carotid Artery Stenting.

Ahmed Elmashad1,2, Danison Emmerson1,2, Allison Gorseth3, Matthew N Jaffa2.   

Abstract

Ticagrelor is a frequent component of dual antiplatelet therapy (DAPT) following carotid artery stent placement. Hemorrhagic complications remain the focus of most reports, however, other adverse events must also be known to the prescribing physician. Angioedema is a rare and potentially life-threatening complication reported following ticagrelor administration and we present 1 such case here with a review of the existing literature.
© The Author(s) 2022.

Entities:  

Keywords:  angioedema; carotid stenting; stroke; ticagrelor

Year:  2022        PMID： 35755229      PMCID： PMC9214928          DOI： 10.1177/19418744221097353

Source DB:  PubMed          Journal:  Neurohospitalist        ISSN： 1941-8744


  11 in total

1.  The Yale algorithm. Special workshop--clinical.

Authors:  M S Kramer; T A Hutchinson
Journal:  Drug Inf J       Date:  1984

2.  Stent thrombosis redux--the FDA perspective.

Authors:  Andrew Farb; Ashley B Boam
Journal:  N Engl J Med       Date:  2007-02-12       Impact factor: 91.245

3.  First report of hypersensitivity to ticagrelor.

Authors:  Kieran L Quinn; Kim A Connelly
Journal:  Can J Cardiol       Date:  2014-04-13       Impact factor: 5.223

4.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

5.  A Case Series of 18 Patients Receiving Ticagrelor After Carotid Stenting.

Authors:  Elizabeth M Olafson; Jodi R DeGrote; Alexander Drofa; Evgueni Kouznetsov; Michael Manchak; Nathan D Leedahl; David D Leedahl
Journal:  J Pharm Pract       Date:  2017-09-07

6.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.

Authors:  Claes Held; Nils Asenblad; Jean Pierre Bassand; Richard C Becker; Christopher P Cannon; Marc J Claeys; Robert A Harrington; Jay Horrow; Steen Husted; Stefan K James; Kenneth W Mahaffey; José C Nicolau; Benjamin M Scirica; Robert F Storey; Marius Vintila; Joseph Ycas; Lars Wallentin
Journal:  J Am Coll Cardiol       Date:  2010-12-30       Impact factor: 24.094

7.  Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department.

Authors:  Aleena Banerji; Sunday Clark; Michelle Blanda; Frank LoVecchio; Brian Snyder; Carlos A Camargo
Journal:  Ann Allergy Asthma Immunol       Date:  2008-04       Impact factor: 6.347

8.  Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke.

Authors:  M D Hill; T Lye; H Moss; P A Barber; A M Demchuk; N J Newcommon; T L Green; C Kenney; A Cole-Haskayne; A M Buchan
Journal:  Neurology       Date:  2003-05-13       Impact factor: 9.910

9.  Ticagrelor-induced Angioedema After Percutaneous Coronary Intervention in a Patient with a History of Ischemic Stroke and Low Response to Clopidogrel: A Rare Dilemma.

Authors:  Paramarajan Piranavan; Nirmal J Kaur; Fady Marmoush; Andrew Burton; Joseph Hannan
Journal:  Cureus       Date:  2018-12-11

10.  Ticagrelor-Induced Angioedema: A Rare and Unexpected Phenomenon.

Authors:  Rajeev Seecheran; Valmiki Seecheran; Sangeeta Persad; Sasha Lalla; Naveen Anand Seecheran
Journal:  Case Rep Cardiol       Date:  2017-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.